产品介绍
Product Description
Biochem/physiol Actions
RLA8 is an orally available and potent agonist of peroxisome proliferator-activated receptors (PPARs)-α/γ/δ and G-protein-coupled receptor 40 (GPR40). RLA8 reverses the proregression of pathological changes such as hepatic lipid accumulation, steatosis, inflammation and fibrosis in mice models of nonalcoholic steatohepatitis (NASH). Also, it improves serum HDL cholesterol, reduce hepatic free fatty acid and triglyceride levels, and alleviate insulin resistance.
orally available and potent agonist for PPARs-α/γ/δ and GPR40 that exhibits efficacy to reverse nonalcoholic steatohepatitis and fibrosis
技术参数
Specifications
| Quality Level | 100 |
| assay | ≥98% (HPLC) |
| form | powder |
| storage condition | protect from light |
| color | white to beige |
| solubility | DMSO: 2 mg/mL, clear |
| storage temp. | 2-8°C |
| SMILES string | O(CCCCCCCC(=O)O)c1cc(cc(c1)\C=C\c2ccc(cc2)OC)OC |
| InChI | 1S/C24H30O5/c1-27-21-13-11-19(12-14-21)9-10-20-16-22(28-2)18-23(17-20)29-15-7-5-3-4-6-8-24(25)26/h9-14,16-18H,3-8,15H2,1-2H3,(H,25,26)/b10-9+ |
| InChI key | MNKZDYGBWDHRMX-MDZDMXLPSA-N |
